Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease (CD) that commonly 12 causes an increased size of cardiomyocytes in the left ventricle. The proteins myosin and actin 13 interact in the myocardium to produce contraction through the actomyosin ATPase cycle. The 14 duty ratio (r) of myosin is the proportion of the actomyosin ATPase cycle that myosin is bound 15 to actin and does work. A common hypothesis is that HCM mutations increase contraction in 16 cardiac sarcomeres; however, the available data is not clear on this connection. Based on 17 previous work with human α-cardiac actin (ACTC), we hypothesize that HCM-linked ACTC 18 variants with alterations near the myosin binding site have an increased r, producing more force. 19
Introduction 27
Cardiovascular disease (CD) is the most costly global disorder and has become the 28 greatest cause of mortality in the world, being responsible for one third of deaths worldwide with 29 immense economic costs ("WHO | Cardiovascular diseases (CVDs)" 2016). In Canada alone, 30
where there are more than 35 million people, over $20 billion is spent annually to treat CD 31 The functional units of the heart muscle are sarcomeres which contain actin and myosin 37 proteins. These interact together in a power stroke, shortening the sarcomeres, leading to muscle 38 contraction. The power stroke requires the hydrolysis of ATP by myosin when bound to actin 39 (Fox, 2012) . The force produced by myosin and actin in the sarcomere is termed the ensemble 40 force and can be calculated with the equation: 41 F EN = N t ·f i · r, (Eq 1) 42
where N t is the number of individual actomyosin interactions, f i is the force per actomyosin 43 interaction, and r is the duty ratio of myosin (Sommese et al. 2013 ). The myosin duty ratio is the 44 proportion of the actomyosin ATPase cycle that myosin is bound to actin and can be calculated 45 using the equation: 46 r = (k cat ·δ)/v o (Eq 2) 47 where k cat is the k cat of myosin's ATPase activity, v o is the velocity of the enzyme, and δ is the 48 step size of myosin (Howard 1997). 7 to the lysate and mixed at 4˚C overnight. After centrifugation at 25,000 rpm in a TA 25.50 rotor 119 (Beckman) for 30 minutes, the supernatant was recirculated through a 5 mL Ni-NTA column 120 (Qiagen) in a closed loop for 1.5 hours. The column was then washed with 30 mL of Buffer A 121 containing 50 mM KCl followed by 40 mL of Buffer A containing 50 mM KCl and 20 mM 122 imidazole. A 1 mL HiTrap DEAE Sepharose FF column (GE Healthcare Life Science) 123 equilibrated in 10 mM Tris, pH 8.0, 0.2 mM CaCl 2 , 1 mM ATP, 0.125 mM PMSF, 0.2 mM β-124 mercaptoethanol was attached to the bottom of the Ni-NTA column. 40 mL ACTC release buffer 125 (10 mM Tris, pH 8.0, 50 mM KCl, 0.2 mM EGTA, 0.2 mM PMSF, 0.5 mM MgCl 2 , 0.2 mM 126 ATP, 2 mM β-mercaptoethanol) was applied to release the ACTC protein from the His-tagged 127 G4-6 bound on the Ni-NTA column. The released ACTC protein then bound to the DEAE 128 column. After disconnecting the DEAE column, the His-tagged G4-6 protein was eluted from the 129 Ni-NTA column in 15 mL G4-6 elution buffer (10 mM Tris, pH 8.0, 50 mM KCl, 0.2 M 130 imidazole, pH 8.0, 5 mM CaCl 2 , 1 mM PMSF, 1 mM ATP, 2 mM β-mercaptoethanol). ACTC 131 was eluted from the DEAE column in ACTC elution buffer (10 mM Tris, pH 8.0, 0.2 mM CaCl 2 , 132 0.2 mM ATP, 0.2 mM PMSF, 0.2 mM β-mercaptoethanol, 0.3 M KCl). ACTC-containing 133 fractions were dialyzed into G-buffer (2 mM Tris pH 8, 0.2 mM CaCl 2 , 0.2 mM ATP, 0.5 mM ß-134 mercaptoethanol, 0.002% NaN 3 ). Proteins were kept on ice and used within one week of 135 preparation. 10% SDS-PAGE was used to verify the presence of pure ACTC and the progress of 136 For personal use only. This Just-IN manuscript is the accepted manuscript prior to copy editing and page composition. It may differ from the final official version of record. molar ratio of gelsolin to ACTC, and 2 mM Mg-ATP. Gelsolin is added to the ATPase assay to 147 reduce viscosity of high F-actin concentrations, increasing the accuracy in the experiment 148 (Sommese et al. 2013 ). Samples of varying actin concentrations were produced through serial 149 dilutions in AB containing 2 mM Mg-ATP and kept on ice until they were added to the reaction. 150
The ATPase assay was performed using two 96-well plates at 22˚C. The reaction plate 151 contained concentrations of H 2 PO 4 ranging from 0.05 mM to 2 mM for a standard curve and 152 triplicate 100 µL samples of each ACTC concentration. Rabbit soleus muscle myosin was 153 prepared in 1X AB without ATP to a final concentration of 0.125 mg/mL. 100 µL of myosin was 154 added to each actin sample well to begin the ATPase reaction (final concentration of 0.063 155 mg/mL or 0.13 umol/L). At 10 minute intervals for 40 min, 45 µL of each reaction mixture was 156 removed and mixed with 45 µL stop solution (60 mM EDTA pH 6.5, 6.6% SDS) in wells of the 157 stop plate. Over the course of the assay, the ATPase rate was linear for all ATC variants (data 158 note shown). The standard samples were also mixed with 45 µL stop solution. 159
After 40 min, 200 µL of a molybdate colouring solution (0.25M 2% ammonium 160 molybdate, 5 mg/ml ferrous sulfate) were added to the wells of the stop plate and the plate was 161 then read at 750 nm in a microplate reader. The standard curve was used to calculate the rate of 162 inorganic phosphate release in each assay. The average of the triplicate ATPase activities for 163 each concentration of actin was plotted against the concentration of actin in the assay and fit to 164 The in vitro motility assay was adapted from Toyoshima (1987) and performed at 22˚C. Dahari and Dawson 2015). We also observed a significant increase between WTrec and F90∆ 227
Assuming a fixed step size of 5 nm for myosin, we then calculated the duty ratio of each 229 ACTC variant, r, and the relative myosin duty ratio with respect to WTrec ACTC, r rel (Table 1) To test our hypothesis, we first purified recombinant human ACTC variant proteins 243 employing His-tagged G4-6 affinity chromatography (Ohki et al. 2009 ). We showed that tissue-244 purified bovine ACTC protein and human WTrec protein did not exhibit any statistically 245 significant differences in myosin ATPase assays, indicating that the His-tagged G4-6 purification 246 method does not affect the activity of the resulting proteins. 247
We predicted that variants in the actomyosin binding site would follow the pattern of the 248 well-studied E99K ACTC variant, exhibiting an increase in myosin duty ratio; however, our data 249 from ATPase and in vitro motility assays showed variability between the actomyosin site of 250 other ACTC variants. In ATPase assays, E99K and H88Y ACTC variants exhibited activities 251 similar to WTrec, while R95C and F90∆ had lower ATPase activities. In the in vitro motility 252 assays, E99K ACTC had lower sliding velocities, while R95C and F90∆ variants exhibited 253 higher velocities. The H88Y ACTC had a similar velocity to WTrec. Taken together, the 254 For personal use only. This Just-IN manuscript is the accepted manuscript prior to copy editing and page composition. It may differ from the final official version of record. calculated duty ratios based on a 5 nm myosin step size resulted in a duty ratio relative to WTrec 255 that was higher for E99K ACTC, consistent with our previous work (Dahari and Dawson 2015), 256 lower for R95C and F90∆ ACTC and similar for H88Y ACTC. 257
The hypothesis that a change in the same binding site will result in the same molecular 258 dysfunction does not account for the nature of that change. The E99K substitution results in a 259 charge-reversal at a site that is predicted to participate in a salt bridge with a counterpart amino to gain a fuller picture, we also need to examine added layers of biological complexity involving 278 the products of other genes that are mutated in patients suffering HCM (Maron 2013) , such as 279 examining regulated thin filaments in vitro or reconstituted thin filaments using sinusoidal 280 analysis (Bai et al. 2014 (Bai et al. , 2015 . Integration of data from several levels of cardiac function 281 regulation will connect molecular defects to HCM development. These connections will allow us 282 to target specific changes in individual patients, tailoring treatments and leading to longer and 283 better lives. 284 285 Acknowledgements 286
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